This early-phase trial tests a new treatment called AB-2100 for people with advanced or metastatic clear-cell renal cell carcinoma that has come back after standard treatments. AB-2100 is made from the patient's own immune cells, which are modified in the lab to better recognize …
Phase: PHASE1, PHASE2 • Sponsor: Arsenal Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC